[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP013923A - Derivados de indol-3-ilo - Google Patents

Derivados de indol-3-ilo

Info

Publication number
ECSP013923A
ECSP013923A EC2001003923A ECSP013923A ECSP013923A EC SP013923 A ECSP013923 A EC SP013923A EC 2001003923 A EC2001003923 A EC 2001003923A EC SP013923 A ECSP013923 A EC SP013923A EC SP013923 A ECSP013923 A EC SP013923A
Authority
EC
Ecuador
Prior art keywords
derivatives
ilo
indol
nomm
inflammations
Prior art date
Application number
EC2001003923A
Other languages
English (en)
Inventor
Rudolf Gottschlich
Matthias Wiesner
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP013923A publication Critical patent/ECSP013923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Derivados de indol-3-ilo de la fórmula general I que detallo en el gráfico, donde A,B,X,R1,R2,R3,R4,R5, n o m m tienen el significado indicado en la reivindicación 1 así como sus sales y solvatos fisiológicamente inofensivos son inhibidores de la integrina y se pueden aplicar para el tratamiento de trombosis, infarto del miocardio, enfermedades cardiacas coronarias, arteriosclerosis, inflamaciones, tumores, osteoporosis, artritis reumática , enfermedad degenerativa muscular, retinopatía diabética, infecciones y restenosis después de angioplastia o en procesos patológicos que se originan o propagar debido a una angiogénesis.
EC2001003923A 2000-02-11 2001-02-09 Derivados de indol-3-ilo ECSP013923A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10006139A DE10006139A1 (de) 2000-02-11 2000-02-11 Indol-3-yl-Derivate

Publications (1)

Publication Number Publication Date
ECSP013923A true ECSP013923A (es) 2002-09-27

Family

ID=7630611

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001003923A ECSP013923A (es) 2000-02-11 2001-02-09 Derivados de indol-3-ilo

Country Status (27)

Country Link
US (1) US6743810B2 (es)
EP (1) EP1254133B9 (es)
JP (1) JP4938194B2 (es)
KR (1) KR20020073585A (es)
CN (1) CN1214026C (es)
AR (1) AR027398A1 (es)
AT (1) ATE293620T1 (es)
AU (2) AU2001231664C1 (es)
BR (1) BR0108154A (es)
CA (1) CA2399813C (es)
CO (1) CO5261548A1 (es)
CZ (1) CZ20022616A3 (es)
DE (2) DE10006139A1 (es)
EC (1) ECSP013923A (es)
ES (1) ES2240400T3 (es)
HU (1) HUP0302671A2 (es)
IL (1) IL151154A0 (es)
MX (1) MXPA02007732A (es)
NO (1) NO20023770L (es)
NZ (1) NZ521260A (es)
PE (1) PE20011125A1 (es)
PL (1) PL356427A1 (es)
PT (1) PT1254133E (es)
RU (1) RU2257380C2 (es)
SK (1) SK11152002A3 (es)
WO (1) WO2001058893A2 (es)
ZA (1) ZA200207273B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US20040138284A1 (en) * 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
JP2004521079A (ja) * 2000-08-29 2004-07-15 ファルマシア・コーポレーション アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物
BR0115077A (pt) * 2000-11-01 2003-12-23 Merck Patent Ges Mit Beschroen Métodos e composições para o tratamento de doenças dos olhos
GB0028367D0 (en) * 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
ES2376161T3 (es) * 2001-01-29 2012-03-09 Janssen Pharmaceuticals, Inc. Indoles sustituidos y su utilización como antagonistas de integrinas.
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
CN1536998A (zh) 2001-08-01 2004-10-13 Ĭ��ר�����޹�˾ 用于治疗眼病的整联蛋白抑制剂
WO2003068253A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
KR100732440B1 (ko) * 2002-08-30 2007-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 질소 함유 방향환 유도체
CA2521135A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
CA2523245C (en) * 2003-04-28 2012-03-06 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
US7211588B2 (en) 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
EP1667668B1 (en) * 2003-10-01 2008-07-02 MERCK PATENT GmbH Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
JP2007536344A (ja) * 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
EP1828144A2 (en) * 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
CN102335168B (zh) * 2011-10-25 2014-04-02 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
AU2015304465B2 (en) 2014-08-18 2019-05-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
AU720758B2 (en) * 1996-04-10 2000-06-08 Merck & Co., Inc. Alphavbeta3 antagonists
KR20000035880A (ko) * 1996-08-27 2000-06-26 이곤 이 버그 도파민 ｄ2 효능제 및 5ｈｔ1ａ 리간드로서의 4-아미노에톡시 인돌
WO1999033798A1 (fr) * 1997-12-25 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Derives heterocycliques azotes
DE69932414T2 (de) * 1998-02-23 2007-02-22 South Alabama Medical Science Foundation, Mobile Indol-3-propionsäure, salze und ester davon als arzneimittel #
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
AU3386199A (en) * 1998-04-08 1999-10-25 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
ES2182509T3 (es) * 1998-04-08 2003-03-01 Wyeth Corp Derivados de n-ariloxietilamina para el tratamiento de la depresion.
JP4425699B2 (ja) * 2004-05-17 2010-03-03 川崎重工業株式会社 小型滑走艇

Also Published As

Publication number Publication date
AU3166401A (en) 2001-08-20
JP2003530319A (ja) 2003-10-14
IL151154A0 (en) 2003-04-10
RU2257380C2 (ru) 2005-07-27
EP1254133A2 (de) 2002-11-06
CN1214026C (zh) 2005-08-10
SK11152002A3 (sk) 2003-01-09
CN1398264A (zh) 2003-02-19
DE50105955D1 (de) 2005-05-25
RU2002123332A (ru) 2004-01-10
NO20023770D0 (no) 2002-08-09
ZA200207273B (en) 2003-12-10
EP1254133B1 (de) 2005-04-20
NZ521260A (en) 2004-02-27
WO2001058893A2 (de) 2001-08-16
CZ20022616A3 (cs) 2002-10-16
BR0108154A (pt) 2003-01-21
AU2001231664C1 (en) 2006-10-05
NO20023770L (no) 2002-08-09
AR027398A1 (es) 2003-03-26
AU2001231664B2 (en) 2006-02-23
CA2399813A1 (en) 2001-08-16
CA2399813C (en) 2010-03-09
PL356427A1 (en) 2004-06-28
HUP0302671A2 (hu) 2003-12-29
US20030045728A1 (en) 2003-03-06
EP1254133B9 (de) 2005-09-07
CO5261548A1 (es) 2003-03-31
DE10006139A1 (de) 2001-08-16
US6743810B2 (en) 2004-06-01
PT1254133E (pt) 2005-09-30
MXPA02007732A (es) 2002-10-11
ES2240400T3 (es) 2005-10-16
PE20011125A1 (es) 2001-11-07
HK1051863A1 (en) 2003-08-22
WO2001058893A3 (de) 2002-04-18
KR20020073585A (ko) 2002-09-27
ATE293620T1 (de) 2005-05-15
JP4938194B2 (ja) 2012-05-23

Similar Documents

Publication Publication Date Title
ECSP013923A (es) Derivados de indol-3-ilo
ES2180945T3 (es) Agentes antimicrobianos derivados de azolilpiperazinilfeniloxazolidona.
TR200103431T2 (tr) Alfa V integrin reseptör antagonistleri.
UY26926A1 (es) Derivados de la quinolina y quinazolina
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
PA8580001A1 (es) Compuestos pirimido que tienen actividad antiproliferativa
NO20011453D0 (no) Arylsulfonanilid urea
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
CY1107475T1 (el) Αναστολεις ρο-κινασης
DE60144064D1 (de) Sulfone, die die aktivität von gamma-secretase modulieren
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
NO986090L (no) Fenylalaninderivater som integrininhibitorer
ATE523194T1 (de) Bis(thiohydrazidamide) in kombination mit taxol für die behandlung von krebs
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
BR0008310A (pt) Derivados de alfa-alanina
PA8531701A1 (es) Derivados de pirimidina
BR0116202A (pt) Derivados de uréia e uretano como inibidores de integrinas
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
AR030376A1 (es) Derivados aza-aminoacidos (inhibidores del factor xa-15)
NO20020131L (no) Diacylhydrazinderivater
ATE352307T1 (de) Zusammensetzung zur behandlung von tumoren oder krebs, welche fluorouracil und ein methylol übertragungsmittel enthält
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
ATE248845T1 (de) Arylsulfonanilid-phosphate